This map shows the geographic impact of J Zoldan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Zoldan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Zoldan more than expected).
This network shows the impact of papers produced by J Zoldan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Zoldan. The network helps show where J Zoldan may publish in the future.
Co-authorship network of co-authors of J Zoldan
This figure shows the co-authorship network connecting the top 25 collaborators of J Zoldan.
A scholar is included among the top collaborators of J Zoldan based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with J Zoldan. J Zoldan is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
19 of 19 papers shown
1.
Blumen, Sergiu C., Anat Kesler, Ron Dabby, et al.. (2013). Oculopharyngeal muscular dystrophy among Bulgarian Jews: a new cluster?. PubMed. 15(12). 748–52.7 indexed citations
2.
Huminer, David, et al.. (2003). Hereditary partial transcobalamin II deficiency with neurologic, mental and hematologic abnormalities in children and adults.. PubMed. 5(12). 868–72.22 indexed citations
3.
Zoldan, J, et al.. (2000). Pergolide as adjunct therapy in Parkinson's disease evaluated using SPES. Revista Médica Del Hospital General De México. 63(3). 155–164.2 indexed citations
Zoldan, J, et al.. (1996). Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease.. PubMed. 69. 541–4.26 indexed citations
11.
Melamed, E., et al.. (1996). Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy.. PubMed. 69. 545–50.40 indexed citations
12.
Zoldan, J, et al.. (1996). Reply from the Authors. Neurology. 47(6). 1609–1609.1 indexed citations
Huminer, David, et al.. (1995). Multiple symmetric lipomatosis presenting with polyneuropathy.. PubMed. 31(11). 693–5.7 indexed citations
15.
Wysenbeek, A J, L. Leibovici, & J Zoldan. (1990). Acute central nervous system complications after pulse steroid therapy in patients with systemic lupus erythematosus.. PubMed. 17(12). 1695–6.22 indexed citations
16.
Zoldan, J, et al.. (1988). Transient regional and migratory osteoporosis. A possible neural mechanism.. PubMed. 24(4-5). 201–6.6 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.